BR112018006480A2 - ?vetor, método de tratamento de uma doença ou condição, composição, combinação de um vetor, kit, uso de um vetor, método para a modulação in vivo da atividade eletrofisiológica de uma célula - Google Patents
?vetor, método de tratamento de uma doença ou condição, composição, combinação de um vetor, kit, uso de um vetor, método para a modulação in vivo da atividade eletrofisiológica de uma célulaInfo
- Publication number
- BR112018006480A2 BR112018006480A2 BR112018006480A BR112018006480A BR112018006480A2 BR 112018006480 A2 BR112018006480 A2 BR 112018006480A2 BR 112018006480 A BR112018006480 A BR 112018006480A BR 112018006480 A BR112018006480 A BR 112018006480A BR 112018006480 A2 BR112018006480 A2 BR 112018006480A2
- Authority
- BR
- Brazil
- Prior art keywords
- vector
- treating
- condition
- cell
- disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000001727 in vivo Methods 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 102000004310 Ion Channels Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235920P | 2015-10-01 | 2015-10-01 | |
| US201562235914P | 2015-10-01 | 2015-10-01 | |
| US201662303907P | 2016-03-04 | 2016-03-04 | |
| US201662378509P | 2016-08-23 | 2016-08-23 | |
| PCT/US2016/054199 WO2017058926A1 (en) | 2015-10-01 | 2016-09-28 | Targeted expression of chloride channels and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018006480A2 true BR112018006480A2 (pt) | 2018-10-09 |
Family
ID=58427328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018006480A BR112018006480A2 (pt) | 2015-10-01 | 2016-09-28 | ?vetor, método de tratamento de uma doença ou condição, composição, combinação de um vetor, kit, uso de um vetor, método para a modulação in vivo da atividade eletrofisiológica de uma célula |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11407812B2 (enExample) |
| EP (1) | EP3355938B1 (enExample) |
| JP (1) | JP7097070B2 (enExample) |
| KR (2) | KR20180072713A (enExample) |
| CN (1) | CN108289965A (enExample) |
| AU (1) | AU2016332847B2 (enExample) |
| BR (1) | BR112018006480A2 (enExample) |
| CA (1) | CA2999279A1 (enExample) |
| HK (1) | HK1252915A1 (enExample) |
| SG (1) | SG10201912703PA (enExample) |
| WO (1) | WO2017058926A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3880179A2 (en) * | 2018-11-14 | 2021-09-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for cns delivery |
| CN110679548B (zh) * | 2019-10-24 | 2021-11-30 | 南方医科大学南方医院 | 一种自闭症小鼠模型的构建方法 |
| CN111759857A (zh) * | 2020-06-30 | 2020-10-13 | 宁波市微循环与莨菪类药研究所 | Gabrd甲基化靶点在制备抗海洛因复吸药物中的应用 |
| CN115480485B (zh) * | 2022-09-14 | 2024-09-10 | 南开大学 | 一种基于数据驱动模型的软镜扭转运动安全控制方法 |
| GB202401492D0 (en) | 2024-02-05 | 2024-03-20 | Ucl Business Ltd | Chloride channels and uses thereof |
| CN119331917B (zh) * | 2024-10-28 | 2025-10-17 | 北京爱思益普生物科技股份有限公司 | 能够表达GlyR α1/β型GlyR的细胞株及其制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3644643A (en) * | 1969-10-13 | 1972-02-22 | Unimed Inc | Method of reducing intraocular pressure using glycine |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US5527703A (en) | 1994-05-25 | 1996-06-18 | Merck & Co., Inc. | DNA encoding glutamate gated chloride channels |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| DE60139398D1 (de) * | 2000-06-20 | 2009-09-10 | Bionomics Ltd | Mutation, welche mit epilepsie assoziiert ist |
| WO2002066606A2 (en) * | 2001-02-16 | 2002-08-29 | Bristol-Myers Squibb Company | Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, hgra4, and splice variant thereof |
| US20040058313A1 (en) | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| US8298818B2 (en) * | 2006-04-28 | 2012-10-30 | University Of Florida Research Foundation, Inc. | Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter |
| DK2061891T3 (da) | 2006-08-24 | 2012-07-23 | Virovek Inc | Ekspression i insektceller af gener med overlappende åbne læserammer, fremgangsmåder og sammensætninger hertil |
| WO2008143875A1 (en) | 2007-05-14 | 2008-11-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Targeted delivery of glycine receptors to excitable cells |
| EP2058401A1 (en) * | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
| EP2283038A1 (en) * | 2008-04-30 | 2011-02-16 | Dublin City University | Compositions and methods for expressing in-frame multimeric proteins |
| JP5775819B2 (ja) * | 2008-10-09 | 2015-09-09 | ハワード ヒューズ メディカル インスティチュート | 新規なキメラリガンド開口型イオンチャネルおよびその使用方法 |
| US20130184318A1 (en) | 2010-04-30 | 2013-07-18 | The Regents Of The University Of California | Modulating compliance of trabecular meshwork |
| WO2012155091A1 (en) | 2011-05-11 | 2012-11-15 | Kirax Corporation | Package for improved treatment of conditions |
| EP2877213B1 (en) * | 2012-07-25 | 2020-12-02 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
| EP2692868A1 (en) * | 2012-08-02 | 2014-02-05 | Universitat Autònoma De Barcelona | Adeno-associated viral (AAV) vectors useful for transducing adipose tissue |
| WO2014093251A1 (en) * | 2012-12-10 | 2014-06-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Engineered receptors and their use |
| WO2015106005A1 (en) | 2014-01-08 | 2015-07-16 | Circuit Therapeutics, Inc. | Method for therapeutic management of ocular hypertension |
| AU2015237140A1 (en) | 2014-03-27 | 2016-10-13 | Circuit Therapeutics, Inc. | System and method for therapeutic management of cough |
| JP2017531652A (ja) | 2014-10-06 | 2017-10-26 | アルスロジェン ビー．ブイ．Ａｒｔｈｒｏｇｅｎ Ｂ．Ｖ． | Ａａｖに基づく遺伝子治療 |
| KR20200108514A (ko) | 2015-09-17 | 2020-09-21 | 코다 바이오테라퓨틱스 인코포레이티드 | 신경 장애를 치료하기 위한 조성물 및 방법 |
| GB2547179A (en) | 2015-10-26 | 2017-08-16 | Quethera Ltd | Genetic construct |
| KR20180134846A (ko) | 2016-04-21 | 2018-12-19 | 바이로베크 인코포레이티드 | 곤충 세포에서의 aav 생산, 및 이를 위한 방법 및 조성물 |
-
2016
- 2016-09-28 EP EP16852497.3A patent/EP3355938B1/en active Active
- 2016-09-28 HK HK18112264.4A patent/HK1252915A1/zh unknown
- 2016-09-28 BR BR112018006480A patent/BR112018006480A2/pt not_active IP Right Cessation
- 2016-09-28 SG SG10201912703PA patent/SG10201912703PA/en unknown
- 2016-09-28 JP JP2018536695A patent/JP7097070B2/ja active Active
- 2016-09-28 US US15/764,733 patent/US11407812B2/en active Active
- 2016-09-28 CA CA2999279A patent/CA2999279A1/en not_active Abandoned
- 2016-09-28 AU AU2016332847A patent/AU2016332847B2/en active Active
- 2016-09-28 CN CN201680068232.8A patent/CN108289965A/zh active Pending
- 2016-09-28 WO PCT/US2016/054199 patent/WO2017058926A1/en not_active Ceased
- 2016-09-28 KR KR1020187012245A patent/KR20180072713A/ko not_active Ceased
- 2016-09-28 KR KR1020257000627A patent/KR20250012721A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016332847B2 (en) | 2023-08-10 |
| KR20180072713A (ko) | 2018-06-29 |
| JP7097070B2 (ja) | 2022-07-07 |
| AU2016332847A1 (en) | 2018-04-19 |
| CN108289965A (zh) | 2018-07-17 |
| EP3355938A4 (en) | 2019-03-06 |
| EP3355938B1 (en) | 2024-02-07 |
| EP3355938A1 (en) | 2018-08-08 |
| KR20250012721A (ko) | 2025-01-24 |
| HK1252915A1 (zh) | 2019-06-06 |
| AU2016332847A2 (en) | 2023-08-03 |
| SG10201912703PA (en) | 2020-02-27 |
| JP2018533976A (ja) | 2018-11-22 |
| US11407812B2 (en) | 2022-08-09 |
| US20190010210A1 (en) | 2019-01-10 |
| CA2999279A1 (en) | 2017-04-06 |
| WO2017058926A1 (en) | 2017-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018006480A2 (pt) | ?vetor, método de tratamento de uma doença ou condição, composição, combinação de um vetor, kit, uso de um vetor, método para a modulação in vivo da atividade eletrofisiológica de uma célula | |
| MX2015009963A (es) | Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía. | |
| MY181458A (en) | Variant rnai | |
| BR112017013599A2 (pt) | composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras. | |
| EA201891142A1 (ru) | Контроль клеточных окислительно-восстановительных уровней | |
| BR112017004349A2 (pt) | terapia com gene de globina para o tratamento de hemoglobinopatias | |
| BR112013018352A2 (pt) | composição de minociclina tópica e método | |
| PE20170140A1 (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer | |
| EP3845241A8 (en) | Long lasting effect of new botulinum toxin formulations | |
| BR112015009746A2 (pt) | Agente que aumenta atividade de glicocerebrosidase em mamíferos | |
| MX387788B (es) | Uso de agentes activos durante tratamientos quimicos. | |
| BR112018008503A2 (pt) | método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer | |
| WO2012170931A3 (en) | Compounds that modulate intracellular calcium | |
| UY34328A (es) | ?composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan protoporfirinógeno ix oxidasa?. | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| MX2016002077A (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| MY181928A (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| MX337711B (es) | Compuestos que modulan el calcio intracelular. | |
| PH12013501688A1 (en) | Treatment of amyotrophic lateral sclerosis using umbilical derived cells | |
| BR112015001697A2 (pt) | formulações de clomazona | |
| BR112016016578A2 (pt) | Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma | |
| MX376776B (es) | Zscan4 para usarse en el tratamiento de enfermedades y condiciones asociadas con una anormalidad de los telómeros. | |
| BR112015002295A2 (pt) | métodos e composições para indução in vivo de formação de célula beta pancreática | |
| BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat | |
| BR112015018047A8 (pt) | método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2742 DE 25-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |